Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Apr 2022
Eisai statement on the Centers for Medicare and Medicaid Services’ National coverage determination with coverage with evidence development for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
8 April 2022 - Eisai stands with people living with Alzheimer’s disease and their families, health care professionals and other ...
Posted by Michael Wonder on 08 Apr 2022
TGA approved Yuflyma
8 April 2022 - The TGA has approved yet another adalimumab biosimilar. ...
Posted by Michael Wonder on 08 Apr 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine (Comirnaty), for use as a booster for individual aged 12–15 years old
8 April 2022 - The TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, Comirnaty, for use as a ...
Posted by Michael Wonder on 07 Apr 2022
What is the solution to America’s deepening access to medicines crisis?
7 April 2022 - Last week, a bill to limit the cost of insulin in the US passed the House of ...
Posted by Michael Wonder on 07 Apr 2022
CMS finalises Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
7 April 2022 - Today, the CMS released a national policy for coverage of aducanumab (Aduhelm) and any future monoclonal antibodies ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 07 Apr 2022
Clayton Pharmaceuticals and VistaPharm receive FDA approval for sucralfate oral suspension
7 April 2022 - Approval validates the use of novel pathway for bioequivalence of complex generic drug products, which increases ...
Posted by Michael Wonder on 07 Apr 2022
Concerns two different flu vaccines create two tier system for 65 and overs
8 April 2022 - PHARMAC is being accused of kicking an own goal on flu jabs, after those aged 65 ...
Posted by Michael Wonder on 07 Apr 2022
BeiGene’s Brukinsa quickly passes HIRA’s reimbursement review
7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
A radical treatment for insulin pricing
6 April 2022 - A private, non-profit company recently announced that it intends to bypass the traditional supply chain and sell ...
Posted by Michael Wonder on 07 Apr 2022
TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (Xevudy) for the BA.2 omicron sublineage
7 April 2022 - The TGA has received an application from GSK for a higher (1,000 mg) dose of its ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...
Posted by Michael Wonder on 07 Apr 2022
Innovent announces the approval of Pemazyre (pemigatinib) by the NMPA for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement as confirmed by a validated diagnostic test that have progressed after at least one prior line of systemic therapy
6 April 2022 - Innovent Biologics announced that the National Medical Products Administration has approved Pemazyre (pemigatinib) for the treatment of ...